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Abstract
The Alzheimer’s Association International Conference held its sixth Satellite Symposium in Sydney, Australia in 2019, highlighting the leadership of Australian researchers
in advancing the understanding of and treatment developments for Alzheimer’s disease (AD) and other dementias.
This leadership includes the Australian Imaging, Biomarker, and Lifestyle Flagship
Study of Ageing (AIBL), which has fueled the identification and development of many
biomarkers and novel therapeutics. Two multimodal lifestyle intervention studies have
been launched in Australia; and Australian researchers have played leadership roles in
other global studies in diverse populations.
Australian researchers have also played an instrumental role in efforts to understand
mechanisms underlying vascular contributions to cognitive impairment and dementia;
and through the Women’s Healthy Aging Project have elucidated hormonal and other
factors that contribute to the increased risk of AD in women. Alleviating the behavioral
and psychological symptoms of dementia has also been a strong research and clinical
focus in Australia.
KEYWORDS

Alzheimer’s, dementia, behavioral symptoms, biomarkers, prevention

INTRODUCTION

collaborations.1 Since 2015, the Alzheimer’s Association International
Conference (AAIC) has helped fuel the globalization of AD research

The worldwide effort to identify and develop effective therapies

through its Satellite Symposia, a series of international meetings

for Alzheimer’s disease (AD) and other dementias has accelerated

designed to highlight regional research and place it in the context of

in recent years with increased funding and a proliferation of global

the global effort to identify new cures and treatments for AD and other
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dementias. Launched in 2015 in Mexico City, AAIC Satellite Symposia
have also been held in Varna, Bulgaria; Buenos Aires, Argentina; Ben-

RESEARCH IN CONTEXT

galuru, India; and Sao Paulo, Brazil. In 2019, the Association selected
1. Systematic Review: The authors report the updates and

Sydney, Australia for a Satellite Symposia to ensure the strategic align-

advances in Alzheimer’s disease and dementia research

ment of dementia research in Australia with that of the international

presented at the Alzheimer’s Association International

research community.

Conference (AAIC) Satellite Symposium in Sydney.

Research in Australia has been instrumental in advancing global

2. Interpretation: The findings highlight both established

efforts to better understand the disease and develop strategies and

and emerging research from Oceania spanning biomark-

technologies that will lead to improved treatments and cures. Accord-

ers, novel therapeutics, risk factors, and dementia care.

ing to Dementia Australia, an estimated 459,000 Australians currently

3. Future Directions: Previous AAIC Satellite Symposia

live with dementia, with this number predicted to grow to more than

have been hosted by Mexico City, Mexico; Varna, Bul-

1.1 million by 2058. Dementia is the second leading cause of death

garia; Buenos Aires, Argentina; Bengaluru, India; and São

among all Australians and the most common cause of death among

Paulo, Brazil. The 2021 AAIC Satellite Symposia, hosted

women. The cost of caring for Australians with dementia was estimated

in collaboration with the Global Brain Health Institute,

at $14.25 billion in 2016.2

will be a virtual conference that will explore dementia

The National Health and Medical Research Council (NHMRC), Aus-

research in the Mediterranean region.

tralia’s chief funding agency for medical research, announced its Boosting Dementia Research Initiative in 2014, which committed $200 million over 5 years and established the National Institute for Dementia Research (NNIDR) in July 2015 to coordinate an expansion of
dementia research. In 2018, $20 million was committed to estab-

2.1

Molecular imaging

lish the Australian Dementia Network to bring together researchers
to create a national dementia clinical quality registry, to network

Imaging of processes and pathologies at the molecular level through

and standardize memory clinics, and to boost participation in clinical

positron emission tomography (PET), magnetic resonance spec-

trials.

troscopy (MRS), and optical retinal imaging techniques improves diag-

At the Sydney Symposium, Australian scientists joined with other

nostic and prognostic accuracy. Until relatively recently, these tech-

leaders in the field to focus on translation of research into new inter-

nologies were used primarily in research settings; however, as tech-

ventions, including novel biomarkers and novel therapeutics. Investi-

nologies have improved over the years and better reagents have

gators shared the latest discoveries regarding genetic and vascular

become available, they have begun to be incorporated into clinical

risk factors as well as multidomain lifestyle interventions designed to

care. For example, Austin Health in Melbourne currently performs

address these risk factors and treat the behavioral and psychological

≈1000 brain fluorodeoxyglucose (FDG)-PET scans each year. These

symptoms of dementia (BPSD).

scans assess brain glucose metabolism and provide much greater sensitivity and specificity in diagnosing AD compared to clinical diagnosis
when verified against pathological findings,3 leading to more appropriate management of patients with dementia.4

2

BIOMARKERS

The advent of amyloid PET imaging has taken the specificity of diagnosis to an even higher level.5 As demonstrated in the AIBL study,

The development of AD biomarkers has fueled much of the progress

advances in amyloid PET imaging have also proven useful in predicting

in understanding the neuropathological and clinical progression of

the development of mild cognitive impairment (MCI) and AD in cogni-

the disease and in developing a range of intervention strategies. The

tively normal adults.6 Now, with a standardized method for quantitat-

Australian Imaging, Biomarker, and Lifestyle Flagship Study of Ageing

ing amyloid plaque deposition across multiple scanners and using dif-

(AIBL), launched in 2006 as a longitudinal prospective study of cogni-

ferent PET ligands by using a scale of 0 to 100 “Centiloid units,” amyloid

tion in people over the age of 60, capitalized on the pioneering work

imaging has become even more useful as a diagnostic tool.7 Amyloid

of Colin Masters, Christopher Rowe, and others at the University of

imaging as a tool for identifying early pathological changes in the AD

Melbourne. At the time of the Sydney Satellite Symposium, AIBL had

brain has also been incorporated into revised diagnostic criteria devel-

enrolled and collected longitudinal data from 2500 participants. These

oped by the International Working Group (IWG),8 the National Insti-

data are freely available to researchers worldwide.
AIBL, in collaboration with the Alzheimer’s Disease Neuroimaging

tute on Aging and Alzheimer’s Association (NIA-AA) working group,9
and the recent NIA-AA Research Framework.10

Initiative (ADNI), is credited with identifying and developing many the

Molecular imaging also may play multiple important roles in clinical

important AD biomarkers currently used in both research and clinical

trials: (1) for proof of target engagement; (2) to estimate target floor

settings and continues to lead the field in the discovery and develop-

and ceiling values for trial inclusion; (3) to predict cognitive decline

ment of novel biomarkers, particularly in the areas of molecular imag-

and disease progression, which can be used to stratify participants;

ing and blood biomarkers.

and (4) as an outcome measure to monitor effectiveness. Amyloid PET

4
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imaging has been incorporated in many recent clinical trials for

pendent datasets, the investigators showed that a composite of plasma

these purposes. For example, in a phase 2 trial of the monoclonal

biomarkers showed a diagnostic accuracy of 90% when amyloid PET

antibody bapineuzumab, amyloid PET imaging demonstrated that

was used as the standard of truth.18 Several other plasma biomarker

bapineuzumab blunts amyloid accumulation in the

brain11

whereas

assays in development have shown similar levels of accuracy (e.g.,

another monoclonal antibody, aducanumab, has been shown to reduce

Schindler et al.19 ). More recent longitudinal data further shows that

plaque burden.12 These differences in kinetics may result from the

plasma Aβ levels track with cognitive decline.

antibodies targeting different forms of amyloid beta (Aβ), which

A novel and very promising blood biomarker for AD-type tau pathol-

could explain differences in therapeutic efficacy at different stages of

ogy is p-tau181. In 2018, a study using an electrochemiluminescence

disease.13 These findings also need to be considered when using PET

(ECL) immunoassay developed at Lilly Research Laboratories in the

as an outcome measure in clinical trials.

United States reported increased plasma p-tau181 in AD and cor-

AIBL has collected >1600 PET amyloid scans, making it the largest

relations with both and amyloid and tau PET.20 These findings were

longitudinal study of amyloid imaging. A 2013 paper showed for the

replicated in a large cohort using the same ECL immunoassay, also

first time that amyloid load as measured by PET begins to rise about 20

demonstrating that plasma and cerebrospinal fluid (CSF) levels of p-

years before cognitive impairment is apparent, and more recent data

tau181 correlate strongly, and that p-tau181 levels are normal in other

has refined understanding of the relationship between the amount of

neurodegenerative disorders.21 Importantly, the increase in plasma p-

amyloid present in the brain and subtle changes in cognition as well as

tau181 was significant before amyloid PET, but after CSF and plasma

the effect of apolipoprotein E (APOE) ε4 carriage.14,15 Recent research

Aβ42, at sub-PET threshold amyloid pathology.21 Very similar results

has also revealed that in the AD brain, amyloid exists in multiple bio-

were found using a novel assay based on the Simoa platform, validated

chemical “pools” comprising both soluble and insoluble forms, but that

in four independent cohorts, also in patients with cognitive complaints

PET only quantifies insoluble forms deposited as plaque. University of

in the primary care setting.22 Importantly, plasma p-tau181 measured

Melbourne researchers are exploring the relationship of different Aβ

by Simoa in samples taken 8 years prior to autopsy could differenti-

pools with PET amyloid values across the continuum of the disease.

ate AD from non-AD neurodegenerative diseases in neuropatholog-

More recently, tau PET imaging has emerged as a tool for identifying

ically confirmed cases with high (area under the curve [AUC] 0.97)

early signs of neurodegeneration and monitoring disease progression

accuracy.23 These data support plasma p-tau181 as a robust blood

in presymptomatic stages; and there have also been substantial molec-

biomarker that shows promise for implementation in clinical diagnos-

ular imaging advances to assess neuroinflammation, another hallmark

tic routine.

of AD pathogenesis.

2.3
2.2

Novel biomarkers

Blood biomarkers
Other novel biomarkers discussed at the Sydney Satellite Sympo-

Blood-based biomarkers have the potential to provide easily accessi-

sium included markers of mitochondrial abnormalities and inflamma-

ble and cost-effective solutions for the detection of pathological signs

tion, such as molecular imaging of the mitochondrial translocator pro-

of AD, but until recently had been thought to lack the required analyti-

tein (TSPO)24 and mitochondrial complex I;24,25 endothelial-derived

cal sensitivity to measure proteins derived from the brain in peripheral

plasma exosome proteins that may serve as markers of vascular contri-

blood samples. However, recent technological advances, specifically

butions to cognitive impairment and dementia (VCID);27,28 other CSF,

ultrasensitive immunoassays and mass spectrometry techniques, have

plasma, and clinical biomarkers of VCID; advanced magnetic resonance

enabled dramatic improvements in the ability to quantify AD biomark-

imaging (MRI) markers of VCID;29 and retinal imaging biomarkers of

ers in blood. Recent blood biomarker studies incorporate not only vari-

amyloid, vascular changes, and neurodegeneration.30–36

ous species of Aβ and the neurodegeneration biomarker neurofilament

Alpha-synuclein is a biomarker associated with synucleinopathies

light (NfL), but also novel methods for assessing levels of phosphory-

such as Parkinson’s disease (PD) and dementia with Lewy bodies (DLB)

lated tau (p-tau). Consequently, these assays show great promise for

but also represented in limbic cerebral areas in both MCI and AD.37

use as screening tests, as well as tools to study AD pathophysiology

Recent studies demonstrated that measurement in CSF with innova-

in clinical, epidemiological, and genetic research. The development of

tive techniques (real-time quaking-induced conversion test assay [RT-

blood biomarkers reflecting the complex and heterogeneous patho-

QuIC]17 and protein misfolding cyclic amplification [PMCA]38 ) or in

physiology of AD is the cornerstone for early diagnosis, reliable prog-

peripheral red blood cells39,40 could enrich the biomarker array for a

nosis, and drug response prediction. In addition, as AD is multifaceted,

precise stratification of typical and atypical phenotypes of AD.

it’s likely that a multiple biomarker approach will be needed for a correct stratification of the disease and its tailored treatment.17
A recent collaboration between scientists from Australia and Japan

3

NOVEL THERAPEUTICS

demonstrates the utility of plasma Aβ biomarkers to predict brain amyloid burden. Using a technique combining immunoprecipitation with

Disappointing clinical trials of amyloid-targeting AD therapies have

mass spectrometry (IP-MS), and applying the technique to two inde-

propelled the development of alternative therapeutic approaches.

5
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Among those discussed at the Sydney Satellite meeting were

In a mouse model of tauopathy, Götz et al. showed that repeated

immunotherapies and other compounds that target tau by inhibiting

SUS treatments also cleared neuronal tau and improved motor and

kinases or aggregation or stabilizing microtubules. Because tau pathol-

memory functions through the induction of autophagy.59 They have

ogy correlates more strongly with the severity of dementia than Aβ

since upscaled their research to test the approach in sheep, an animal

pathology, targeting tau may be more efficacious than targeting Aβ

model with a more human-like skull,60 and are moving toward human

once cognitive impairment begins. Sigurdsson provided an overview

safety trials and optimization of the technique in humans.

of the work of his laboratory in which initial studies demonstrated
the efficacy of active and passive tau immunotherapies.41,42 These
studies have since been confirmed and extended by numerous groups,
resulting in several ongoing clinical trials.43 Currently, his group is

4
TARGETING VASCULAR, GENETIC, AND
LIFESTYLE RISK FACTORS

clarifying the mechanisms of tau antibody therapies, and developing
tau antibody fragments, including single domain antibodies derived

Vascular risk factors including diabetes, hypertension, smoking, and

from llama, both for in vivo detection of tau and as therapeutic

stroke have long been known to increase the risk of cognitive decline

agents.44–46

and dementia.61 While the impact of stroke on the development of

Another target that has received increasing attention in the AD field

dementia is seen primarily in late life, exposure to cardiovascular

and at the Sydney meeting is inflammation. Inflammation appears to

risk factors in early and mid-life has also been linked to cognitive

contribute substantially to disease progression in AD and other neu-

worsening.62 Moreover, multiple mechanisms have been shown to con-

rodegenerative diseases, with the brain-resident innate immune cells

tribute to VCID, including ischemia, inflammation, oxidative stress, and

called microglia as key effector cells.47

Genetic studies have also iden-

impaired amyloid clearance; and other factors that may contribute

tified immune-related genes as important risk factors. Thus, although

throughout a person’s life course including low socioeconomic status,

trials of anti-inflammatory drugs have failed thus far to show efficacy

low literacy, and environmental factors have been linked to poorer car-

in AD, targeting inflammatory pathways and other interacting path-

diovascular fitness and thus, cognitive decline.

ways such as metabolic and insulin resistance pathways continue to

Australian researchers are among the leaders in efforts to better

be viewed as potentially promising therapeutic strategies.48 For exam-

understand both the mechanisms underlying VCID and the potential to

ple, INmuneBio, with support from the Alzheimer’s Association, is cur-

identify modifiable risk factors to prevent cognitive decline. For exam-

rently conducting a Phase 1 study of XPro1595®, a drug that inhibits

ple, they lead the Stroke and Cognition consortium (STROKOG), an

inflammation by selectively targeting and neutralizing soluble tumor

international consortium that has developed harmonized methods for

necrosis factor (TNF). TNF has been shown to affect multiple metabolic

collecting longitudinal data from individuals who had a stroke or are at

and immune pathways and contribute to insulin resistance and AD49

elevated risk of stroke or transient ischemic attack (TIA).63 STROKOG

and XPro1595 has been shown in multiple AD mouse models to be neu-

has merged data from >18,000 participants in 28 studies conducted

roprotective and anti-inflammatory but not immunosuppressive.49–53

in 17 countries. A recent analysis of data from 13 studies in 8 coun-

The trial, funded by the Alzheimer’s Association Part the Cloud Trans-

tries confirmed a high prevalence of post-stroke cognitive impairment

lational Research program, is underway at five sites across Australia.

(PSCI) and identified a history of past stroke, diabetes, hypertension,

One of the challenges in developing treatments for AD is the blood-

smoking, atrial fibrillation, and congestive heart failure as factors that

brain barrier, a continuous endothelial membrane that seals off the

increase the risk of PSCI.64 The study further highlighted differences

circulating blood from the interstitial space in the

brain.54

Numerous

among different ethno-racial groups in terms of the influence of various

physiological transport systems have been exploited to deliver drugs

risk factors. Other studies that have contributed to the understanding

across the blood-brain barrier and direct infusions into the brain have

of the interplay among vascular disease, cognition, diabetes, and func-

been developed but have met with limited success.

tional cognitive indicators such as gait include the Tasmanian Study of

One novel non-invasive approach being developed at the University
of Queensland in Brisbane, Australia, uses low-intensity ultrasound in

Cognition and Gait (TASCOG) and the Cognition and Diabetes in Older
Tasmanians (CDOT) study.

combination with intravenously injected microbubbles to transiently

Worldwide, women have a higher prevalence of dementia than

and safely disrupt the blood-brain barrier.55 Testing this approach in

men,65 and female sex is the second strongest risk factor for late-onset

a mouse model of AD, Götz et al. have demonstrated the ability of

AD after advanced age.66 Factors that may contribute to the elevated

repeated treatments with scanning ultrasound (SUS) to reduce amyloid

risk of dementia in women include longer lifespan, genetics, hormonal

plaque burden and restore memory even in the absence of anti-amyloid

differences, and an increased prevalence of metabolic and vascular risk

drugs.56 They went on to show that the technique does not increase

factors.67,68 Research has shown that heart disease in women differs

cerebral amyloid angiopathy (CAA) or microbleeds, which are thought

from that in men in terms not only of risk factors but in symptoms and

to be associated with an increased risk of vascular dementia and that

approaches to management and prevention; and similar sex differences

SUS also stimulates microglia activation and increased phagocytosis of

are now being revealed in dementia research studies.

amyloid.57 Moreover, they have shown that SUS facilitates the uptake

The influence of sex hormones on dementia risk remains poorly

of therapeutic antibodies by the brain and into neurons more than ten-

studied and understood although there is substantial evidence point-

fold, suggesting SUS as a drug delivery tool.58

ing to dramatic brain effects associated with hormonal changes

6
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during the menopausal transition.69 For 30 years, the Women’s

Given the AIBL research group’s focus on lifestyle, it is no surprise that

Healthy Aging Project (WHAP), a longitudinal study of Australian-born

they have led the way in clinical and physiological studies investigat-

women, has been collecting multi-domain data—including hormone

ing the links between AD and exercise, sleep, diet, and other modifiable

levels; cognitive measurements; brain imaging; and vascular, genetic,

lifestyle factors, including their interaction with genetic factors.

and lifestyle risk factors—on women through the menopausal transition and into aging.70,71 Recent research by Szoeke et al. at the University of Melbourne showed that the combination of APOE ε4 and
midlife dyslipidemia compounded the risk of brain amyloid deposition

4.1
FINGERS and other global efforts to combat
dementia

in late life.72 These findings may help explain why carriage of APOE ε4
increases the risk of developing AD to a greater extent in women than

The World-Wide FINGERS (WW-FINGERS) network, co-led by the

in men.73

FINGERS team and the Alzheimer’s Association, aims to replicate the

APOE ε4 is the strongest known genetic risk factor for AD, yet mul-

landmark Finnish Geriatric Intervention Study to Prevent Cognitive

tiple international genome-wide association studies (GWAS) have also

Impairment (FINGER) in different populations.86 FINGER was the first

identified 40 susceptibility loci and are using functional genomics stud-

large study to demonstrate that a multidomain intervention combin-

ies to map these loci to genes, variants, and genetic pathways.74

Across

ing exercise, diet, cognitive training, and vascular risk monitoring could

multiple sites in Australia, AIBL researchers have investigated whether

prevent cognitive decline in elderly participants at risk of cognitive

it is possible to develop polygenic risk scores (PRS) to predict pre-

decline based on their cardiovascular risk score.87 WW-FINGERS stud-

clinical cognitive decline. While their research indicates that AD risk-

ies in the United States (U.S. POINTER), Singapore (SINGER), Australia

weighted PRS are no better than APOE ε4 alone in predicting cognitive

(AU-ARROW), China (MIND-CHINA), four European countries (MIND-

decline, combining AD risk genes with genes associated with cognition

ADmini), and the Basque population (GOIZ ZAINDU) use harmonized

and using phenotypic weighting appears to have some utility for pre-

clinical trial methods and outcome measures adapted to the specific

dicting cognitive performance.75–77

geographical, ethnic, cultural characteristics, and lifestyle practices of

While genetic factors clearly increase the risk of dementia, there is

their populations.

also strong evidence that lifestyle and environment also play important

Since the AAIC-SS in Sydney, the Alzheimer’s Association and the

roles in increasing dementia, leading research groups worldwide to

Medical Research Future Fund have funded the launch and implemen-

study whether lifestyle interventions may mitigate that risk. A recent

tation of the Australian Multidomain Approach to Reduce Demen-

study showed that a favorable lifestyle is associated with decreased

tia Risk by Protecting Brain Health with Lifestyle Intervention (AU-

risk.78

Thus,

ARROW). The AU-ARROW intervention and assessment model builds

given the overwhelming evidence that mid-life exposure to vascular

on AIBL research findings and a lifestyle intervention study that

risk factors contribute to AD,79 recent primary prevention studies have

demonstrated improved cognition and increased cerebral glucose

focused on lifestyle modifications to reduce these risk factors.

metabolism resulting from a combination of physical activity with com-

dementia incidence even in older adults at high genetic

Evidence for the benefits of physical activity on cognition are par-

puterized brain training.88 The 2-year trial will be conducted in Sydney

ticularly intriguing in part because of the face validity of putative

and Perth, comparing a multidomain intervention (aerobic exercise,

mechanisms: improved cardiovascular health and cerebral blood flow,

nutritional counseling, computerized cognitive training, social engage-

increased neuroplasticity and neurogenesis, and increases in blood

ment, and vascular risk monitoring) with a control group receiving

levels of mediators of these physiological functions, including brain-

health education and support. AU-ARROW has been harmonized to the

derived neurotrophic factor (BDNF), insulin growth factor 1 (IGF-1),

U.S. POINTER study, which is wholly funded and led in collaboration

vascular growth factors, homocysteine, and nitric oxide.80 In Australia,

with the Alzheimer’s Association. This coordination is a key aspect for

investigators enrolled older adult participants from the AIBL study in

both studies, and supported through WW FINGERS.

a 24-month physical activity intervention trial (the AIBL Active Study),

Also in Australia, investigators have launched a 3-year online multi-

which demonstrated excellent adherence and positive cardiovascular

modal lifestyle intervention study called Maintain Your Brain (MYB),

health benefits, suggesting that physical intervention may reduce risk

aimed at reducing cognitive decline in older adults.89 If effective, this

factors for dementia.81 The study also demonstrated that among older

intervention could be easily and broadly implemented in diverse popu-

adults, long-term adherence to physical activity interventions is fea-

lations.

sible. Another trial in Australia—the Individual Goal Setting (INDIGO)

Other global studies have been examining other aspects of cogni-

study—uses peer mentors and goal setting as motivators to increase

tive impairment in diverse populations around the world. For exam-

physical activity among sedentary community-dwelling older adults

ple, starting in 2012, the Cohort Studies of Memory in an Interna-

with subjective memory complaints (SMC) or MCI.82 Sleep distur-

tional Consortium (COSMIC) began collecting and harmonizing data

bances and unhealthy diet have also been associated with increased

from population-based longitudinal studies of aging and dementia, now

brain amyloid burden.83,84 In the case of the former, AIBL researchers

including 41 cohorts in 31 countries across six continents.90 By explor-

factors.85

ing risk factors that contribute to cognitive decline across 20 cohorts,

This emphasizes the importance of understanding gene–environment

including different ethno-racial groups, Lipnicki et al. showed that cer-

interactions to improve potential efficacy of lifestyle interventions.

tain risk factors such as high cholesterol, diabetes, smoking, and female

have shown this to be significantly moderated by genetic

7

SEXTON ET AL.

sex are more strongly associated with cognitive decline among Asians
than Whites, suggesting that prevention strategies may need to be

5
THE ROLE OF PSYCHOGERIATRICS IN
DEMENTIA CARE

adapted according to geography and ethnicity.91 Brain structural and
neuropathological changes have also been shown to differ among indi-

For patients and caregivers, behavioral and psychological symptoms

viduals with dementia from diverse ethnic and racial groups.92 In Aus-

associated with dementia are among the most burdensome.102 Agi-

tralia, increased dementia prevalence and incidence was demonstrated

tation, delusions, hallucinations, sleep disturbances, and apathy occur

among Aboriginal and Torres Strait Islander peoples compared to non-

commonly in patients with dementia as well as in patients with depres-

Aboriginal older people93 and has led to the development and valida-

sion, and many patients with a psychiatric disorder mimicking dementia

tion of cognitive and well-being assessments and resources for Aborig-

actually have other conditions that are treatable, such as depression or

inal people94,95 community models of dementia care,96 and interven-

apathy.103 -105

tional partnerships such as the Dementia Prevention and Risk Manage-

International consensus groups including the International Psy-

ment Program for Aboriginal Australians (DAMPAA) program aimed at

chogeriatrics Association (IPA), International Society to Advance

reducing dementia risk through exercise, cardiovascular risk manage-

Alzheimer’s Research and Treatment (ISTAART) Neuropsychiatric

ment, cognitive and social engagement, and education in partnership

Symptoms (NPS) Professional Interest Area (PIA), and other expert

with Aboriginal community–controlled health services and communi-

panels have begun to develop diagnostic criteria for agitation, psy-

ties.

chosis, and apathy in major and minor neurocognitive disorders (the

Globally, efforts are also underway to increase participant engage-

terminology advocated as a replacement for “dementia’’ in the Diag-

ment and recruitment efficiency in clinical studies worldwide. In Aus-

nostic and Statistical Manual for Mental Disorders, 5th edition [DSM-

tralia, for example, StepUp for Dementia Research is a platform that

5]).82–84 These criteria are essential for developing appropriate phar-

connects individuals with research studies. Similar platforms have

macological and non-pharmacological interventions.

also been developed in the United States (the Alzheimer’s Associa-

Several studies in different parts of the world have documented

tion’s TrialMatch®, Banner Health’s Alzheimer’s Prevention Registry,

that many people in residential long-term care facilities have

and UCSF’s Brain Health Registry): the United Kingdom (Join Demen-

treatable psychiatric disorders but receive inappropriate drug

tia Research); and Netherlands (Amsterdam UMC VU University’s

treatments.106–109 In Australia, two studies—the Halting Antipsy-

Hersenonderzoek).

chotic Use in Long-Term Care (HALT) trial and the Reducing Use

The Journal of Alzheimer’s Disease recently published a special issue

of Sedatives (RedUSe) trial have achieved reductions in the use of

from the International Research Network on Dementia Prevention

psychotropic medications.110,111,17 These investigators and others

(IRNDP). The IRNDP is a network of researchers and stakeholders with

advocate an increased focus on non-pharmacological interventions

a common interest in dementia risk reduction, especially incorporating

through a person-centered care paradigm112 and using novel strate-

low- and middle-income countries. The special issue included articles

gies such as humor therapy.113 Another novel approach to reducing

on risk factors, trials, and population-level modeling related to demen-

BPSD in people with dementia is being developed by researchers at

tia risk factors.97 While it highlights the growing evidence suggesting

Griffith University in South East Queensland, Australia. They have

that lifestyle and environmental factors98 may be targeted to reduce

been researching the use of “social robots” with artificial intelligence

the risk of dementia, it also recognizes the substantial knowledge gaps

systems to interact with people and tap into their need for social

that remain and that there are limitations in the quality and quantity of

connections.114 A recent systematic review showed that social robots

evidence.99

were able to improve or increase pleasure affect, decrease depressive

The World Health Organization (WHO) has published the first

symptoms and loneliness scores, increase quality of life, and reduce

global guidelines for risk reduction of cognitive decline and demen-

agitation.115 Indeed, evidence indicates that the use of appropri-

tia. The guidelines, developed using the GRADE methodology involv-

ate technologies can enable older adults to continue living in their

ing a range of international experts, draw mostly from the literature

homes longer, maximize individual autonomy, and promote social

on interventions to reduce risk of dementia and cognitive impair-

participation.116

ment. Observational research was used to inform the guidelines where
there was a lack of randomized controlled trials. There are also guidelines emerging that focus on specific risk factors and populations.
For example, the Australian Dementia Collaborative Research Cen-

6
GUT–BRAIN AXIS REGULATION OF
ALZHEIMER’S DISEASE PATHOLOGY

tres at the University of Melbourne have published physical activity
guidelines for older Australians with MCI or SCD.100 A global call for

The gut—brain–microbiota axis plays a critical role in determining the

action on dementia risk reduction must involve consumers and clin-

long-term health of the brain. This axis describes a bidirectional com-

icians and be informed by new evidence as it emerges. To that end,

munication between the gut microbiota residing in the gastrointesti-

recommendations for clinicians have been published to guide patients

nal tract and the brain, which influences many of the biochemical and

regarding the potential benefits of physical activity on brain health

vascular processes in the brain at every stage from development to

while taking into account individual patients’ health problems or other

neurodegeneration. The main mechanisms of gut–brain axis commu-

limitations.101

nication include direct vagal signaling, endocrine factors, metabolic
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processes, and immune signaling.117 Variations in the gut microbiota

rounds.” These sessions confirmed that Australian AD research will

due to stress, antibiotic usage, or aging alters the homeostatic pro-

continue to thrive in the coming years.

cesses in the periphery and the brain, ultimately predisposing the aging
population to the accumulation of amyloid plaques and tau tangles. This
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